Facts and hopes on cancer immunotherapy for small cell lung cancer
Clin Cancer Res. 2024 Apr 17. doi: 10.1158/1078-0432.CCR-23-1159. Online ahead of print.ABSTRACTPlatinum-based chemotherapy plus PD-1 axis blockade is the standard of care in the front-line treatment of extensive-stage small cell lung cancer (ES-SCLC). Despite the robust and consistent increase of long-term survival with PD-1 axis inhibition, the magnitude of the benefit from immunotherapy appears lower as compared to other solid tumors. Several immune evasive mechanisms have been shown to be prominently altered in human SCLC, including, among others, T cell exclusion, downregulation of components of the MHC-class I antige...
Source: Clinical Lung Cancer - April 17, 2024 Category: Cancer & Oncology Authors: Jon Zugazagoitia Handerson Osma Javier Baena Álvaro C Ucero Luis Paz-Ares Source Type: research
Solitary Pulmonary Perivascular Epithelial Cell Tumor Mimicking Pulmonary Metastasis on 68Ga-DOTATATE PET/CT in a Patient With Pancreatic Neuroendocrine Tumor
We report the findings of 68Ga-DOTATATE PET/CT in a 56-year-old woman with solitary pulmonary perivascular epithelioid cell tumor. 68Ga-DOTATATE PET/CT showed a lesion with intense uptake in the region of pancreatic head and a solitary nodule with moderate uptake in the left lung. Pancreatic neuroendocrine tumor with pulmonary metastasis was considered. The postoperative pathological results showed a benign perivascular epithelioid cell tumor of the lung. This case emphasizes the need to increase awareness of benign perivascular epithelioid cell tumors in the differential diagnosis of solitary pulmonary nodule with moderat...
Source: Clinical Lung Cancer - April 17, 2024 Category: Cancer & Oncology Authors: Shuang Liang Xiaoliang Chen Source Type: research
Federated Learning Survival Model and Potential Radiotherapy Decision Support Impact Assessment for Non-small Cell Lung Cancer Using Real-World Data
CONCLUSION: Federated learning over multiple institution data can be used to develop and validate decision support systems for lung cancer while quantifying the potential impact of their use in practice. This paves the way for personalised medicine, where decisions can be based more closely on individual patient details from routine care.PMID:38631978 | DOI:10.1016/j.clon.2024.03.008 (Source: Clinical Lung Cancer)
Source: Clinical Lung Cancer - April 17, 2024 Category: Cancer & Oncology Authors: M Field S Vinod G P Delaney N Aherne M Bailey M Carolan A Dekker S Greenham E Hau J Lehmann J Ludbrook A Miller A Rezo J Selvaraj J Sykes D Thwaites L Holloway Source Type: research
Chest wall tumor following intravesical BCG instillation for non-muscle invasive bladder cancer
We present a case of an isolated subcutaneous chest wall abscess in an immunocompetent 52-year-old patient nearly two years after intravesical BCG instillation for NMIBC, an absolute rarity. As the enlarging chest wall tumor may be misinterpreted as malignancy, its expedient diagnosis and prompt treatment are of critical importance.PMID:38623461 | PMC:PMC11017275 | DOI:10.1016/j.jctube.2024.100438 (Source: Clinical Lung Cancer)
Source: Clinical Lung Cancer - April 16, 2024 Category: Cancer & Oncology Authors: Marc Hartert Claudia Deppe Ludger Fink Jutta Kappes Source Type: research
Application Value of CYFRA21-1 Combined with NSE, CEA, and SCC-Ag in Lung Cancer
CONCLUSIONS: The combined assay of CYFRA21-1, NSE, and CEA addresses the aspects of accuracy, sensitivity, specificity, and economic cost and should be considered as a potential diagnostic test in LC.PMID:38623667 | DOI:10.7754/Clin.Lab.2023.230662 (Source: Clinical Lung Cancer)
Source: Clinical Lung Cancer - April 16, 2024 Category: Cancer & Oncology Authors: Yuping Fu Dandan Li Ya Zhu Sha Yan Xia Wang Zhenshuai Lian Qi Xie Zhi'an He Source Type: research
Exploration of efficacy of different therapy regimens for advanced NSCLC patients with KRAS mutation in the first-line treatment
CONCLUSION: In the first-line treatment, combination regimen has advantages over single regimen. Among them, chemotherapy combined with immunotherapy plus antiangiogenic therapy can achieve significant efficacy benefits.PMID:38625494 | DOI:10.1007/s12094-024-03485-6 (Source: Clinical Lung Cancer)
Source: Clinical Lung Cancer - April 16, 2024 Category: Cancer & Oncology Authors: Ke Wang Manyi Xu Yanhua Wang Chunwei Xu Yue Hao Zhengbo Song Source Type: research
Comparison of efficacy and safety of PD-1/PD-L1 combination therapy in first-line treatment of advanced NSCLC: an updated systematic review and network meta-analysis
CONCLUSION: For patients with advanced non-selective PD-L1 NSCLC, two effective regimens are Pen + CT and Niv + Bev + CT, which rank first in OS and PFS among all patients. Cam + CT and Tor + CT have advantages for OS in patients with SqNSCLC and Non-sqNSCLC, respectively. Niv + Ipi + CT provided the best OS benefit for patients with an ECOG score of 0, while Pem + CT may be the most effective treatment for patients with an ECOG score of 1. Pem + CT has a better effect on female patients and non-smokers. Sin + CT was found to be the most effective treatment for male patients and the smoking subgroup, while Cam + CT was fou...
Source: Clinical Lung Cancer - April 16, 2024 Category: Cancer & Oncology Authors: Yanqing Yang Wei Chen Lixian Dong Lian Duan Pengfei Gao Source Type: research
Real-World Neoadjuvant Treatment Patterns and Outcomes in Resected Non-Small-Cell Lung Cancer
CONCLUSIONS: Patients with resected, stage II-III NSCLC who received neoadjuvant chemo/chemoradiotherapy have high rates of disease recurrence and poor survival outcomes, highlighting need for more effective treatments to improve survival rates.PMID:38627155 | DOI:10.1016/j.cllc.2024.03.006 (Source: Clinical Lung Cancer)
Source: Clinical Lung Cancer - April 16, 2024 Category: Cancer & Oncology Authors: Jessica Donington Xiaohan Hu Su Zhang Yan Song Ashwini Arunachalam Diana Chirovsky Chi Gao Ari Lerner Anya Jiang James Signorovitch Ayman Samkari Source Type: research
Neutrophil-to-Lymphocyte Ratio and Risk of Nodal Metastasis in Early-Stage Lung Adenocarcinoma: A Brief Report From a Multicentric Analysis
Clin Lung Cancer. 2024 Mar 15:S1525-7304(24)00039-1. doi: 10.1016/j.cllc.2024.03.004. Online ahead of print.NO ABSTRACTPMID:38627156 | DOI:10.1016/j.cllc.2024.03.004 (Source: Clinical Lung Cancer)
Source: Clinical Lung Cancer - April 16, 2024 Category: Cancer & Oncology Authors: Filippo Tommaso Gallina Marco Chiappetta Riccardo Taj è Daniele Forcella Carolina Sassorossi Maria Teresa Congedo Jessica Evangelista Isabella Sperduti Filippo Lococo Federico Cappuzzo Enrico Melis Stefano Margaritora Francesco Facciolo Source Type: research
Potential therapeutic targets of fibrosis in inflammatory rheumatic diseases
Best Pract Res Clin Rheumatol. 2024 Apr 15:101945. doi: 10.1016/j.berh.2024.101945. Online ahead of print.ABSTRACTFibrosis is commonly associated with chronic rheumatic diseases, and causes substantial morbidity and mortality. Treatment of fibrosis is extremely challenging but is badly needed, as approved antifibrotic therapies fibrosis do not halt its progression, which will be discussed with a focus on pulmonary fibrosis. Findings from recent studies indicate several therapeutic targets for treating fibrosis. Interleukin-11 is emerging as a fibrogenic cytokine whose activity can be blocked with neutralizing monoclonal an...
Source: Clinical Lung Cancer - April 16, 2024 Category: Cancer & Oncology Authors: Jiang Su Julianna Desmarais Cong-Qiu Chu Jing Zhu Source Type: research
Efficacy and safety analysis of immunotherapy in non-small cell lung cancer patients with MET alterations
CONCLUSION: NSCLC patients with MET alterations can benefit from immunotherapy, especially the patients treated by combined ICI therapy. However, special attention should be paid to the occurrence of grade 3/4 adverse reactions while using the combined ICI therapy.PMID:38627317 | DOI:10.1007/s12094-024-03455-y (Source: Clinical Lung Cancer)
Source: Clinical Lung Cancer - April 16, 2024 Category: Cancer & Oncology Authors: Yanhua Wang Jingwen Wei Manyi Xu Jing Xiang Keda Shao Yue Hao Zhengbo Song Source Type: research
Chest wall tumor following intravesical BCG instillation for non-muscle invasive bladder cancer
We present a case of an isolated subcutaneous chest wall abscess in an immunocompetent 52-year-old patient nearly two years after intravesical BCG instillation for NMIBC, an absolute rarity. As the enlarging chest wall tumor may be misinterpreted as malignancy, its expedient diagnosis and prompt treatment are of critical importance.PMID:38623461 | PMC:PMC11017275 | DOI:10.1016/j.jctube.2024.100438 (Source: Clinical Lung Cancer)
Source: Clinical Lung Cancer - April 16, 2024 Category: Cancer & Oncology Authors: Marc Hartert Claudia Deppe Ludger Fink Jutta Kappes Source Type: research
Application Value of CYFRA21-1 Combined with NSE, CEA, and SCC-Ag in Lung Cancer
CONCLUSIONS: The combined assay of CYFRA21-1, NSE, and CEA addresses the aspects of accuracy, sensitivity, specificity, and economic cost and should be considered as a potential diagnostic test in LC.PMID:38623667 | DOI:10.7754/Clin.Lab.2023.230662 (Source: Clinical Lung Cancer)
Source: Clinical Lung Cancer - April 16, 2024 Category: Cancer & Oncology Authors: Yuping Fu Dandan Li Ya Zhu Sha Yan Xia Wang Zhenshuai Lian Qi Xie Zhi'an He Source Type: research
Exploration of efficacy of different therapy regimens for advanced NSCLC patients with KRAS mutation in the first-line treatment
CONCLUSION: In the first-line treatment, combination regimen has advantages over single regimen. Among them, chemotherapy combined with immunotherapy plus antiangiogenic therapy can achieve significant efficacy benefits.PMID:38625494 | DOI:10.1007/s12094-024-03485-6 (Source: Clinical Lung Cancer)
Source: Clinical Lung Cancer - April 16, 2024 Category: Cancer & Oncology Authors: Ke Wang Manyi Xu Yanhua Wang Chunwei Xu Yue Hao Zhengbo Song Source Type: research
Comparison of efficacy and safety of PD-1/PD-L1 combination therapy in first-line treatment of advanced NSCLC: an updated systematic review and network meta-analysis
CONCLUSION: For patients with advanced non-selective PD-L1 NSCLC, two effective regimens are Pen + CT and Niv + Bev + CT, which rank first in OS and PFS among all patients. Cam + CT and Tor + CT have advantages for OS in patients with SqNSCLC and Non-sqNSCLC, respectively. Niv + Ipi + CT provided the best OS benefit for patients with an ECOG score of 0, while Pem + CT may be the most effective treatment for patients with an ECOG score of 1. Pem + CT has a better effect on female patients and non-smokers. Sin + CT was found to be the most effective treatment for male patients and the smoking subgroup, while Cam + CT was fou...
Source: Clinical Lung Cancer - April 16, 2024 Category: Cancer & Oncology Authors: Yanqing Yang Wei Chen Lixian Dong Lian Duan Pengfei Gao Source Type: research
